Cancer cachexia: Rationale for the MENAC (Multimodal - Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial
dc.contributor.author | Solheim, Tora Skeidsvoll | |
dc.contributor.author | Laird, Barry J. A. | |
dc.contributor.author | Balstad, Trude Rakel | |
dc.contributor.author | Bye, Asta | |
dc.contributor.author | Stene, Guro Birgitte | |
dc.contributor.author | Baracos, Vickie | |
dc.contributor.author | Strasser, Florian | |
dc.contributor.author | Griffiths, Gareth | |
dc.contributor.author | Maddocks, Matthew | |
dc.contributor.author | Fallon, Marie | |
dc.contributor.author | Kaasa, Stein | |
dc.contributor.author | Fearon, Kenneth | |
dc.date.accessioned | 2019-04-25T12:05:05Z | |
dc.date.accessioned | 2019-04-26T07:40:00Z | |
dc.date.available | 2019-04-25T12:05:05Z | |
dc.date.available | 2019-04-26T07:40:00Z | |
dc.date.issued | 2018-02-09 | |
dc.identifier.citation | Solheim TS, Laird, Balstad TR, Bye A, Stene GB, Baracos V, Strasser F, Griffiths G, Maddocks, Fallon M, Kaasa S, Fearon K. Cancer cachexia: Rationale for the MENAC (Multimodal - Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial. BMJ Supportive & Palliative Care. 2018;8:258-265 | en |
dc.identifier.issn | 2045-435X | |
dc.identifier.issn | 2045-435X | |
dc.identifier.issn | 2045-4368 | |
dc.identifier.uri | https://hdl.handle.net/10642/6977 | |
dc.description.abstract | Cancer cachexia is a multifactorial syndrome characterized by an on-going loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support alone. Cachexia has a high prevalence in cancer and a major impact on patient physical function, morbidity and mortality. Despite the consequences of cachexia, there is no licensed treatment for cachexia and no accepted standard of care. It has been argued that the multifactorial genesis of cachexia lends itself to therapeutic targeting through a multimodal treatment. Following a successful phase II trial, a phase III randomized controlled trial of a multimodal cachexia intervention is underway. Termed the MENAC trial (Multimodal – Exercise, Nutrition and Anti-inflammatory medication for Cachexia), this intervention is based on evidence to date and consists of Non-steroidal Anti inflammatory Drugs (NSAID) and eicosapentaenoic acid (EPA) to reduce inflammation, a physical exercise programme using resistance and aerobic training to increase anabolism, as well as dietary counselling and oral nutritional supplements to promote energy and protein balance. Herein we describe the development of this trial - NCT02330926. | en |
dc.language.iso | en | en |
dc.publisher | BMJ Publishing Group | en |
dc.relation.ispartofseries | BMJ Supportive & Palliative Care;Volume 8, Issue 3 | |
dc.rights | This article has been accepted for publication in BMJ Supportive & Palliative Care, 2018, following peer review, and the Version of Record can be accessed online at http://dx.doi.org/10.1136/bmjspcare-2017-001440. © Article author(s) (or their employer(s) 2018. Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs and other images or illustrative material included where a another copyright owner is identified) is permitted strictly pursuant to the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC-BY-NC 4.0). https://creativecommons.org/licenses/by-nc/4.0/ | en |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | |
dc.subject | Cancer cachexia | en |
dc.subject | Medication trials | en |
dc.subject | Cachexia treatment | en |
dc.subject | Multimodal treatment strategies | en |
dc.title | Cancer cachexia: Rationale for the MENAC (Multimodal - Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial | en |
dc.title.alternative | A novel multimodal treatment strategy for cancer cachexia; rationale and motivation for the MENAC (Multimodal – Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial | en |
dc.type | Journal article | en |
dc.type | Peer reviewed | en |
dc.date.updated | 2019-04-25T12:05:05Z | |
dc.description.version | acceptedVersion | en |
dc.subject.hrcs | Kreft: Ressurser og infrastruktur (utvikling av behandlinger og terapeutiske intervensjoner) | |
dc.subject.hrcs | Cancer : Resources and infrastructure (development of treatments) | |
dc.identifier.doi | http://dx.doi.org/10.1136/bmjspcare-2017-001440 | |
dc.identifier.cristin | 1598737 | |
dc.source.journal | BMJ Supportive & Palliative Care |
Tilhørende fil(er)
Denne innførselen finnes i følgende samling(er)
-
HV - Institutt for sykepleie og helsefremmende arbeid [1410]
HV - Department of Nursing and Health Promotion
Med mindre annet er angitt, så er denne innførselen lisensiert som This article has been accepted for publication in BMJ Supportive & Palliative Care, 2018, following peer review, and the Version of Record can be accessed online at http://dx.doi.org/10.1136/bmjspcare-2017-001440.
© Article author(s) (or their employer(s) 2018. Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs and other images or illustrative material included where a another copyright owner is identified) is permitted strictly pursuant to the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC-BY-NC 4.0). https://creativecommons.org/licenses/by-nc/4.0/